
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. is expected to benefit from the positive financial metrics associated with its innovative therapeutics development, highlighted by the company's use of the PREDATOR platform to enhance immune system responses against cancer. The increase in Core Funds From Operations (FFO) guidance to a range of $1.84-$1.88 reflects a significant year-over-year growth of 5.1%, indicating strong operational performance. Additionally, the achieved same-store net operating income (NOI) expansion of 4.1%, alongside a 4.3% growth in blended rent, demonstrates robust demand drivers that may translate favorably for investor sentiment in the biopharmaceutical sector.
Bears say
The analysis indicates a negative outlook for Werewolf Therapeutics due to weakening revenue growth projections, as full-year same-store revenue growth has been revised downward from a range of (0.35%)-1.15% to a new range of (0.20%)-0.40%. Additionally, the decline in the average effective rental rate, coupled with an increase in expenses of 3.8% year-over-year, has resulted in a 2.6% decline in net operating income (NOI). This financial strain is compounded by new lease rate growth underperforming relative to expectations, suggesting potential challenges in revenue generation moving forward.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares